BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Business > article

Janssen finally gives up clinical research into Hanmi's new drug candidate

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : July 4, 2019, 09:58 | Updated : July 4, 2019, 09:58
  • 트위터
  • 페이스북
  • 웨이보

[Hanmi Pharmaceutical]


SEOUL -- Hanmi Pharmaceutical, a major drug maker in South Korea, suffered another setback as Janssen Pharmaceutica, a pharmaceutical company based in Belgium, gave up clinical research into a drug candidate for patients with diabetes and obesity and returned development rights.

Hanmi said in a regulatory filing on Wednesday that Janssen has decided to return rights related to HM12525A, a candidate substance for a new drug that helps diabetes patients lose weight and control blood sugar. Under a 2015 deal valued at $915 million, Janssen, a subsidiary of Johnson & Johnson, has staged phase 2 clinical trials to evaluate the safety and efficacy of HM12525A.

The development of new drugs proceeds through clinical trials commonly classified into four phases over many years. Janssen has tried to prove that the drug candidate works in two ways simultaneously for controlling body weight and managing blood glucose levels.

Janssen's clinical research showed that HM12525A reached the target for weight loss but the blood sugar control of obese patients with diabetes fell short of internal standards, Hanmi said, adding it would not return a $150 million down payment.

The South Korean company would not dump HM12525A as Janssen's research demonstrated its effects as an obesity drug.

Hanmin has seen a series of failures in its new drug development. In October 2016, Boehringer Ingelheim walked away from its $730 million partnership with Hanmi over safety concerns of Olita (Olmutinib) during clinical trials. Hanmi stopped the development of Olita, which used to be touted as a "breakthrough therapy" for patients who have developed a tolerance to existing lung cancer treatments.

In January this year, Eli Lilly and Company, a U.S. pharmaceutical company, returned its right to develop and commercialize Hanmi's new drug candidate for the treatment of immune diseases because interim results showed a lack of efficacy. They had studied the effects of a Bruton's tyrosine kinase (BTK) inhibitor (HM71224) in patients with rheumatoid arthritis to see if it has an effect on prevalent autoimmune diseases.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Hanmi partners with RAPT Therapeutics to develop and commercialize FLX475 for cancer treatment.
    Hanmi partners with RAPT Therapeutics to develop and commerc…
  • .U.S. partner Lily completely walks away from drug deal with Hanmi Pharmaceutical.
    U.S. partner Lily completely walks away from drug deal with …
  • .Hanmi Pharmaceuticals HM43239 anti-cancer drug wins FDA designation.
    Hanmi Pharmaceutical's HM43239 anti-cancer drug wins FDA des…
  • .Prosecutors raid drug maker Hanmis office over short-selling scandal.
    Prosecutors raid drug maker Hanmi's office over short-sellin…
  • .Hanmi partners with American biotech company to develop multiple bispecific antibodies..
    Hanmi partners with American biotech company to develop mult…

Real Time Photo News

  • .​WINNERs Song Mino to officially debut as artist at exhibition for emerging artists.

    ​WINNER's Song Mino to officially debut as artist at exhibition for emerging artists

  • .Netflix to release new original K-drama content in February next year.

    Netflix to release new original K-drama content in February next year

  • .Singer Kang Daniel updates fans on lawsuit against cyberbullies.

    Singer Kang Daniel updates fans on lawsuit against cyberbullies

  • .Rapper DinDin thanks former 2NE1 member Sandara for G-Dragons limited edition shoes .

    Rapper DinDin thanks former 2NE1 member Sandara for G-Dragon's limited edition shoes

  • .Singer Ailee drops winter-themed ballad song Sweater.

    Singer Ailee drops winter-themed ballad song 'Sweater'

Latest News

more+

  • Doosan Group selects Amazon's cloud service as main tool for digital transformation
  • ​WINNER's Song Mino to officially debut as artist at exhibition for emerging artists
  • Merger of food delivery service apps face objection by franchise shop owners
  • Toss fintech operator wins temporary approval to launch new internet-only bank
  • Netflix to release new original K-drama content in February next year
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view